Evaluating unique aspects of quiescent ovarian cancer cell biology for therapeutic targets

评估静息卵巢癌细胞生物学的独特方面以寻找治疗靶点

基本信息

项目摘要

Most ovarian cancer (OvCa) patients develop fatal chemotherapy-resistant disease. Elucidating mechanisms of chemoresistance in OvCa may identify therapeutic targets to prevent or treat relapsed OvCa. One understudied mechanism of chemotherapy resistance in OvCa is quiescence. Quiescent cells are transiently non-proliferating and thus refractory to standard therapies which target rapidly proliferating cells. The over- arching hypothesis of this project is that hypothesis is that understanding the biology of quiescent OvCa cancer cells will identify critical new therapeutic targets to improve patient outcomes. We have used multiple novel approaches to identify and characterize the transcriptional signature of quiescent OvCa cells. This work indicates that quiescent OvCa (qOvCa) cells have several unique characteristics including: (i) a unique Quiescence Associated Secretory Phenotype (QuASP) which drives chemotherapy resistance in non- quiescent cancer cells, and (ii) altered expression of select components of the ubiquitin-proteosome system (UPS) including induction of UBL7. Indeed, our preliminary data indicate that induction of UBL7 is sufficient to drive a quiescent cell phenotype, including the expression of the QuASP. Bio-informatic analysis of quiescent OvCa cell RNAseq data identified the SRF/MRTF transcription pathway as being inversely correlated with the OvCa quiescent signature. Consistent with this, a small molecule inhibitor of SRF/MRTF-mediated transcription, CCG081, (i) induces UBL7, (ii) drives cells into a dense quiescent state, and (iii), indicating a critical role for the UPS in quiescent cell viability, CCG081 sensitizes OvCa cells to proteasome inhibitors. Based on these discoveries, we propose: SA 1: To characterize the OvCa QuASP. We hypothesize that, characterizing the QuASP will identify critical biologic factors related to quiescence. We will identify QuASP factors, validate the expression of QuASP factors in ovarian cancer and other cancer types, and use knockdown and neutralizing antibodies to evaluate the function of these factors in quiescent OvCa cells.SA 2: To determine the role of the UPS and UBL7 in quiescent cancer cells. We hypothesize that UPS changes contribute to the quiescent cell state and are essential for quiescent cell viability. We will identify which components of the UPS contribute to the quiescent phenotype, including expression of the QuASP, and determine if the proteosome is essential to maintain quiescent OvCa cell viability. Finally, we will SA 3: Evaluate the impact of targeting the proteosome quiescent cells in vivo. We hypothesize that the ability to pharmacologically force these residual cells into a quiescent state and then eliminate these quiescent cells via proteosome inhibition will increase cure rates. We will evaluate the therapeutic potential of combined CCG081 and FDA-approved proteosome inhibitors as consolidative therapy after chemotherapy to eradicate residual quiescent cells. Impact: We will define the regulators of OvCa cell quiescence, providing therapeutic targets eradiate to improve patient outcomes.
大多数卵巢癌(OvCa)患者会出现致命的化疗耐药疾病。阐明机制 卵巢癌化疗耐药性的研究可以确定治疗靶点,以预防或治疗复发的卵巢癌。一 OvCa的化疗耐药机制尚待研究。静止细胞是短暂的 非增殖性的,因此对靶向快速增殖细胞的标准疗法是难治的。过度- 这个项目的假设是,假设是,了解生物学的静态 OvCa癌细胞将确定关键的新治疗靶点,以改善患者的预后。我们有 使用多种新方法来鉴定和表征静止OvCa的转录特征, 细胞这项工作表明,静止OvCa(qOvCa)细胞具有几个独特的特征,包括:(i) 一种独特的静止相关分泌表型(QuASP),可驱动非肿瘤患者的化疗耐药性, 静止的癌细胞,和(ii)泛素-蛋白酶体系统的选择组分的改变的表达 (UPS)包括诱导UBL 7。事实上,我们的初步数据表明,UBL 7的诱导足以 驱动静止细胞表型,包括QuASP的表达。静态的生物信息学分析 OvCa细胞RNAseq数据将SRF/MRTF转录途径鉴定为与细胞周期负相关。 OvCa静止特征。与此一致,SRF/MRTF介导的小分子抑制剂 转录,CCG 081,(i)诱导UBL 7,(ii)驱动细胞进入密集的静止状态,和(iii),表明 由于UPS在静止细胞活力中的关键作用,CCG 081使OvCa细胞对蛋白酶体抑制剂敏感。 基于这些发现,我们提出:SA 1:表征OvCa QuASP。我们假设, 表征QuASP将鉴定与静止相关的关键生物因子。我们将确定QuASP 因子,验证QuASP因子在卵巢癌和其他癌症类型中的表达,并使用 敲低和中和抗体,以评价这些因子在静止OvCa细胞中的功能。 确定UPS和UBL 7在静止癌细胞中的作用。我们假设UPS改变了 有助于静止细胞状态并且对于静止细胞活力是必需的。我们会找出 UPS的组分有助于静止表型,包括QuASP的表达,和 确定蛋白体是否是维持静止OvCa细胞活力所必需的。最后,我们将SA 3: 评价体内靶向蛋白体静止细胞的影响。我们假设, 迫使这些残余细胞进入静止状态,然后通过以下方式消除这些静止细胞: 蛋白酶体抑制将增加治愈率。我们将评估联合CCG 081的治疗潜力 和FDA批准的蛋白体抑制剂作为化疗后的巩固治疗, 静止细胞影响:我们将定义OvCa细胞静止的调节因子,提供治疗靶点 辐射,以改善患者的结果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ronald J Buckanovich其他文献

Ronald J Buckanovich的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ronald J Buckanovich', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10713051
  • 财政年份:
    2023
  • 资助金额:
    $ 43.81万
  • 项目类别:
Project 3: Hedgehog Inhibition to Enhance Response to ICI Therapy
项目 3:Hedgehog 抑制增强 ICI 治疗反应
  • 批准号:
    10713054
  • 财政年份:
    2023
  • 资助金额:
    $ 43.81万
  • 项目类别:
HCC Ovarian Cancer SPORE
HCC 卵巢癌孢子
  • 批准号:
    10713050
  • 财政年份:
    2023
  • 资助金额:
    $ 43.81万
  • 项目类别:
Defining the impact of stromal aging on ovarian cancer initiation
定义基质老化对卵巢癌发生的影响
  • 批准号:
    10353485
  • 财政年份:
    2021
  • 资助金额:
    $ 43.81万
  • 项目类别:
Defining the impact of stromal aging on ovarian cancer initiation
定义基质老化对卵巢癌发生的影响
  • 批准号:
    10491889
  • 财政年份:
    2021
  • 资助金额:
    $ 43.81万
  • 项目类别:
Defining the impact of stromal aging on ovarian cancer initiation
定义基质老化对卵巢癌发生的影响
  • 批准号:
    10659225
  • 财政年份:
    2021
  • 资助金额:
    $ 43.81万
  • 项目类别:
ALDH Inhibition as Modulator of Tumor Immunobiology
ALDH 抑制作为肿瘤免疫生物学的调节剂
  • 批准号:
    10392913
  • 财政年份:
    2020
  • 资助金额:
    $ 43.81万
  • 项目类别:
ALDH Inhibition as Modulator of Tumor Immunobiology
ALDH 抑制作为肿瘤免疫生物学的调节剂
  • 批准号:
    10380368
  • 财政年份:
    2020
  • 资助金额:
    $ 43.81万
  • 项目类别:
ALDH Inhibition as Modulator of Tumor Immunobiology
ALDH 抑制作为肿瘤免疫生物学的调节剂
  • 批准号:
    10524133
  • 财政年份:
    2020
  • 资助金额:
    $ 43.81万
  • 项目类别:
ALDH Inhibition as Modulator of Tumor Immunobiology
ALDH 抑制作为肿瘤免疫生物学的调节剂
  • 批准号:
    10649413
  • 财政年份:
    2020
  • 资助金额:
    $ 43.81万
  • 项目类别:

相似海外基金

The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
  • 批准号:
    EP/Z000920/1
  • 财政年份:
    2025
  • 资助金额:
    $ 43.81万
  • 项目类别:
    Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
  • 批准号:
    FT230100276
  • 财政年份:
    2024
  • 资助金额:
    $ 43.81万
  • 项目类别:
    ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
  • 批准号:
    MR/X024261/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.81万
  • 项目类别:
    Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
  • 批准号:
    DE240100388
  • 财政年份:
    2024
  • 资助金额:
    $ 43.81万
  • 项目类别:
    Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
  • 批准号:
    2889694
  • 财政年份:
    2023
  • 资助金额:
    $ 43.81万
  • 项目类别:
    Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
  • 批准号:
    2842926
  • 财政年份:
    2023
  • 资助金额:
    $ 43.81万
  • 项目类别:
    Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
  • 批准号:
    NC/X001644/1
  • 财政年份:
    2023
  • 资助金额:
    $ 43.81万
  • 项目类别:
    Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
  • 批准号:
    2337595
  • 财政年份:
    2023
  • 资助金额:
    $ 43.81万
  • 项目类别:
    Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
  • 批准号:
    2232190
  • 财政年份:
    2023
  • 资助金额:
    $ 43.81万
  • 项目类别:
    Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
  • 批准号:
    23K17514
  • 财政年份:
    2023
  • 资助金额:
    $ 43.81万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了